Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic mel...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 609 252 4621

Website: www.bms.com

Address:

Route 206 & Province Line Road, Princeton, United States

SellasgpsCurativeBAT11 Sep. 16 at 11:56 AM

$SLS $JNJ $AZN $PFE $BMY Let’s see which Pharmaceutical walks away with the biggest prize in Oncology? My money is on $JNJ ✌️🙏❤️‍🩹

1 · Reply

Quantumup Sep. 16 at 10:04 AM

Citizens reiterated $NUVB Market Outperform-$10 NUVL - $GSK $BMY RHHBY PFE Here's what Citizens said in its note: At the World Conference on Lung Cancer, clinical updates for Nuvalent/GlaxoSmithKline's (NUVL/GSK) ROS1 TKI, zidesamtinib, demonstrated a competitive profile in the TKI-naïve setting, but immaturity of the dataset and the two-year head start for NUVB's IBTROZI – which we still view as best-in-class, represent a large hill to climb for the potential newcomer. We maintain our Market Outperform rating and $10 DCF-derived price target for NUVB as we continue to monitor the launch.

0 · Reply

PhantomZ Sep. 16 at 12:13 AM

$MRK $PFE $RVMD $CGON $BMY many posssible combination with IV injected Rutherin when activated by X-rays increases Tumor cell kill 100 fold vs radiation therapy alone. newsfilecorp.com/release/31...

1 · Reply

Quantumup Sep. 15 at 11:18 AM

Stifel y'day reiterated $CTNM Buy-$28 and said -- CTNM announced today that PIPE-307/JNJ-5120/, their selective M1R antagonist, failed its ph2 study in MDD. $JNJ $BMY AGMB PLRX VCRE Here's what Stifel went on to say in its note: https://x.com/Quantumup1/status/2099820032914026501?s=20

0 · Reply

55X_ROI_Q1_2026 Sep. 14 at 2:08 PM

$SLS This current short rigged $2.3B Market cap isn't even Close to What Gps is worth the moment the Imminent Phase 3 Results are Announced. $MRNA added $40B in a day for a Reason $RVMD added Nearly $30B the day its P3 results were announced. reddit.com/r/sellasLifescience $ABBV and $BMY who own Aza VEN know It ain't BAT Causing the Miraculous Survival.

0 · Reply

peacewealth7447 Sep. 14 at 10:45 AM

$SLS $JNJ $BMY $CELG

0 · Reply

jamesmckevitt Sep. 14 at 10:44 AM

$SLS just a quick reminder: Michael Frascello of $JNJ has been studying GPS/REGAL for 1.5 years called it a “game changer” in AML. Katherine Bach Kalin on the board of SLS was part of $BMY huge 74b purchase of $CELG and purchase a huge amount of shares 9 months ago. Michael Anglestein of AstraZenica also stated GPS was a game changer for AML patients. Not one of the board have sold a single share either, I’m down; but not out!

0 · Reply

55X_ROI_Q1_2026 Sep. 14 at 7:52 AM

$SLS $ABBV $BMY BAT for the SLS Control arm Failed 3 Aml remission maintenance trials. what do you think that means? Viale-M Failed in First Remission Viale-T Failed in post Transplant Maintenance Viale C and Verona - Failed

0 · Reply

55X_ROI_Q1_2026 Sep. 14 at 7:01 AM

$SLS $ABBV $BMY Viale-M, T and C Failed

0 · Reply

55X_ROI_Q1_2026 Sep. 14 at 5:07 AM

$SLS $ABBV $BMY Viale-M T and C Failed

1 · Reply

Bristol Myers Squibb Announces Dividend

BMY

Sep 10, 2026, 6:02 PM EDT - 5 days ago

Here are the stocks to favor in the fourth quarter — and those you should avoid

AAPL ABT ADBE AMZN AVGO BAC BMY

Sep 8, 2026, 7:14 AM EDT - 8 days ago

Bristol Myers' blood cancer cell therapy meets main goal in mid-stage trial

BMY

Sep 8, 2026, 6:59 AM EDT - 8 days ago

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel

BMY

Sep 3, 2026, 6:00 PM EDT - 12 days ago

Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research

BMY NVS

Sep 3, 2026, 1:51 AM EDT - 13 days ago

Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

BMY DXCM PWR

Aug 29, 2026, 11:00 AM EDT - 17 days ago

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

BMY

Aug 25, 2026, 12:58 PM EDT - 21 days ago

Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares

BMY

Aug 20, 2026, 9:00 AM EDT - 27 days ago

Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery

BMY

Aug 19, 2026, 5:30 AM EDT - 4 weeks ago

The Key to Pharma M&A: Never Shopping Hungry

AZN BMY

Aug 13, 2026, 5:12 PM EDT - 4 weeks ago

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

BMY

Aug 13, 2026, 4:26 PM EDT - 4 weeks ago

US FDA approves Bristol Myers' blood cancer treatment

BMY

Aug 13, 2026, 12:45 PM EDT - 4 weeks ago

Lawsuit against Bristol Myers over delayed cancer drug is revived

BMY

Aug 13, 2026, 8:00 AM EDT - 4 weeks ago

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

BMY RNA

Aug 10, 2026, 9:01 AM EDT - 5 weeks ago

Bristol Myers to build $2.3 billion manufacturing site in Houston

BMY

Aug 10, 2026, 9:01 AM EDT - 5 weeks ago

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

BMY

Aug 5, 2026, 8:30 AM EDT - 6 weeks ago

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

BMY SDGR

Aug 5, 2026, 8:05 AM EDT - 6 weeks ago

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

AZN BMY

Aug 4, 2026, 1:30 AM EDT - 6 weeks ago

More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

AZN BMY

Aug 3, 2026, 11:38 AM EDT - 6 weeks ago

Astra Buying Bristol Makes No Sense, Fazeli Says

AZN BMY

Aug 3, 2026, 11:20 AM EDT - 6 weeks ago

Bristol-Myers stock: why AstraZeneca merger is unlikely to happen

AZN BMY

Aug 3, 2026, 9:55 AM EDT - 6 weeks ago

Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca

AZN BMY

Aug 3, 2026, 6:43 AM EDT - 6 weeks ago

AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.

AZN BMY

Aug 3, 2026, 6:22 AM EDT - 6 weeks ago

AstraZeneca holds talks with US cancer drug developer in $400bn merger

AZN BMY

Aug 3, 2026, 5:54 AM EDT - 6 weeks ago

Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca

AZN BMY

Aug 3, 2026, 4:46 AM EDT - 6 weeks ago

Why did AstraZeneca shares fall 6% after Bristol Myers Squibb merger reports?

AZN BMY

Aug 3, 2026, 4:06 AM EDT - 6 weeks ago

AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks

AZN BMY

Aug 3, 2026, 3:52 AM EDT - 6 weeks ago

AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

AZN BMY

Aug 3, 2026, 3:20 AM EDT - 6 weeks ago

AstraZeneca shares tumble 7% after reported Bristol Myers talks

AZN BMY

Aug 2, 2026, 5:40 PM EDT - 6 weeks ago

AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report

AZN BMY

Aug 2, 2026, 4:00 PM EDT - 6 weeks ago

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AZN BMY

Aug 2, 2026, 3:36 PM EDT - 6 weeks ago

AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal, FT reports

AZN BMY

Jul 30, 2026, 8:15 AM EDT - 6 weeks ago

Bristol-Myers Squibb Company Earnings Call Transcript: Q2 2026

Jul 30, 2026, 8:15 AM EDT - 6 weeks ago

Bristol-Myers Squibb Company Earnings release: Q2 2026

Jul 30, 2026, 8:15 AM EDT - 6 weeks ago

Bristol-Myers Squibb Company Slides: Q2 2026

Jul 30, 2026, 8:15 AM EDT - 6 weeks ago

Bristol-Myers Squibb Company Quarterly report: Q2 2026

Jul 30, 2026, 7:08 AM EDT - 6 weeks ago

Bristol Myers Lifts Outlook as Profit, Revenue Rise

BMY

Jul 30, 2026, 7:00 AM EDT - 6 weeks ago

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

BMY

Jul 30, 2026, 6:59 AM EDT - 6 weeks ago

Bristol Myers Raises Earnings Guidance as Newer Drugs Drive Big Quarterly Beat

BMY

Jul 30, 2026, 6:59 AM EDT - 6 weeks ago

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

BMY

Jul 20, 2026, 7:01 AM EDT - 1 month ago

Bristol Myers buys Nvidia's latest AI computing system for drug research

BMY NVDA

Jul 20, 2026, 6:59 AM EDT - 1 month ago

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

BMY

$U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma$

Jul 13, 2026, 6:59 AM EDT - 2 months ago

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

BMY

Jun 25, 2026, 12:26 AM EDT - 2 months ago

Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb

BMY INTC PGR

Jun 18, 2026, 6:59 AM EDT - 3 months ago

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

BMY

Jun 17, 2026, 4:16 PM EDT - 3 months ago

Bristol Myers Squibb Announces Dividend

BMY

Jun 17, 2026, 12:30 PM EDT - 3 months ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Jun 17, 2026, 12:00 PM EDT - 3 months ago

3 Stocks to Invest In to Rebalance Your Portfolio

BMY CLX LMT

Jun 11, 2026, 7:03 AM EDT - 3 months ago

Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial

BMY TAK

Jun 9, 2026, 2:00 PM EDT - 3 months ago

Bristol-Myers Squibb Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 3:20 AM EDT - 3 months ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK PFE RDW UTHR XBI

Jun 8, 2026, 6:59 AM EDT - 3 months ago

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

BMY

Jun 3, 2026, 8:00 AM EDT - 3 months ago

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

BMY RCUS

Jun 2, 2026, 8:00 AM EDT - 3 months ago

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

BMY

Jun 1, 2026, 6:59 AM EDT - 3 months ago

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

BMY

SellasgpsCurativeBAT11 Sep. 16 at 11:56 AM

$SLS $JNJ $AZN $PFE $BMY Let’s see which Pharmaceutical walks away with the biggest prize in Oncology? My money is on $JNJ ✌️🙏❤️‍🩹

1 · Reply

Quantumup Sep. 16 at 10:04 AM

0 · Reply

PhantomZ Sep. 16 at 12:13 AM

$MRK $PFE $RVMD $CGON $BMY many posssible combination with IV injected Rutherin when activated by X-rays increases Tumor cell kill 100 fold vs radiation therapy alone. newsfilecorp.com/release/31...

1 · Reply

Quantumup Sep. 15 at 11:18 AM

0 · Reply

55X_ROI_Q1_2026 Sep. 14 at 2:08 PM

0 · Reply

peacewealth7447 Sep. 14 at 10:45 AM

$SLS $JNJ $BMY $CELG

0 · Reply

jamesmckevitt Sep. 14 at 10:44 AM

0 · Reply

55X_ROI_Q1_2026 Sep. 14 at 7:52 AM

0 · Reply

55X_ROI_Q1_2026 Sep. 14 at 7:01 AM

$SLS $ABBV $BMY Viale-M, T and C Failed

0 · Reply

55X_ROI_Q1_2026 Sep. 14 at 5:07 AM

$SLS $ABBV $BMY Viale-M T and C Failed

1 · Reply

55X_ROI_Q1_2026 Sep. 13 at 10:58 PM

$SLS The $ABBV $BMY People Know its GPs. This current short rigged $2.3B Market cap isn't even Close to What is Gps is worth the moment the Imminent Phase 3 Results are Announced. $MRNA added $40B in a day for a Reason $RVMD added Nearly $30B the day its P3 results were announced. https://www.reddit.com/r/sellasLifescience/comments/1weo6k2/comment/p9fbhtj/?screen_view_count=1

0 · Reply

55X_ROI_Q1_2026 Sep. 13 at 6:23 PM

$SLS at 60 events the IDMC UNBLINDED ACTUAL PHASE 3 MOS and IMMUNE RESPONSE DATA! Unblinded Actual Median Overall Survival and Immune Response data from the ongoing P3. $ABBV $BMY Own BAT - they all Know Gps is doing what its done in all 7 prior trials, including 2 Phase 2’s for AML REMISSION MAINTENANCE. and Yes BAT Failed 3 large P3’s and 2 for AML MAINTENANCE - Viale-M - Viale-T FAILED.

0 · Reply

Jwa68 Sep. 13 at 12:45 AM

$COYA $XBI $BMY Remember this previous post. Sticking to my 🔫 Things can change in a split second.

0 · Reply

BioRich Sep. 12 at 4:37 PM

$SLS A lot of you are VERY confused today. We've had drops before, but why is this one different? Why does this feel like doom? Simple: Reality Before yesterday, many have felt it. Many of you started to believe it. Many of you started to venture into the "could it be" territory. And then it hit. Perfect storm. Market up, $SLS tanking. - CEO self-imposed Quiet Period feels like cowardness and hiding - Models that so many relied on are now showing a coin toss - Reality that the run up was tied to tutes capitalizing on a dead ticker - Reality that Shorts remain strong and appear in more control - Reality that the hype was from 10 ad hoc patients of an AML study - Reality that the CEO has been suspect since jump street -Reality that competitors $MRK and $BMY collaborated with $SLS and walked before the collab was complete - Reality $SLS's team history is one of legal and regulatory concerns - Reality that all the BS you thought Bears shared now makes complete sense. $XBI

1 · Reply

peloswing Sep. 11 at 6:06 PM

$BMY Bristol Myers Squibb on clear support here around $63. HSBC price target raised from $60 to $65 ⬆️

0 · Reply

11thestate Sep. 11 at 1:58 PM

$CELG (now $BMY ) investors — there’s no hidden secret here. Just one thing you really need to know. Here’s how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/celgene-investor-settlement

0 · Reply

Quantumup Sep. 11 at 11:42 AM

Cantor reiterated an Overweight rating on $CYTK after its fireside chat w/ mgmt. $EWTX $BMY TECX TENC AZN NVO BAYRY Here's what Cantor said in its note to investors: https://x.com/Quantumup1/status/2098376353619870023?s=20

0 · Reply

BRNDN Sep. 10 at 1:48 PM

$BMY so is this toast

0 · Reply

NetworkNewsWire Sep. 10 at 1:12 PM

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market $QNTM $NVS $MRK $TGTX $BMY https://ibn.fm/A7zHr

1 · Reply

stagetwotrading Sep. 10 at 12:35 PM

$BMY - Grade A Stop loss @ 62.29

0 · Reply

webslinger1978 Sep. 10 at 9:52 AM

$KYTX the first patient ever treated is now well past 2yrs and remains in drug free remission. Plus they have an RMAT designation from the FDA for indication for Multiple Sclerosis. I wouldn’t be surprised if any of the following attempt to acquire $GILD already owns an equity stake, $NVS or $BMY both had to stop their CAR-T clinical trials.

2 · Reply

55X_ROI_Q1_2026 Sep. 10 at 5:06 AM

$SLS $ABBV $BMY $MRNA from $60 to $175 the day its P3 was released. Something very similar about to happen here with SLS.

0 · Reply

Market Cap	130.39B
Revenue (ttm)	48.19B
Net Income (ttm)	7.05B
EPS (ttm)	N/A
PE Ratio	9.93
Forward PE	9.28
Profit Margin	14.64%
Debt to Equity Ratio	1.93

Volume	7,529,800
Avg Vol	12,444,174
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	25%
Beta	0.22
Analysts	Sell
Price Target	$66.30